Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

406 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an international prospective randomized multicenter open-label controlled study. The primary center will be Fernandes Távora Hospital (Fortaleza, Ceará). The aim of this study is to investigate the effects of closed parenteral nutrition systems when compared to open parenteral nutrition systems in terms of several clinical outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition

NCT03792100

Parenteral Nutrition Surgery

COMPLETED PHASE3

Outpatient Preoperative Parenteral Nutrition in Malnourished Surgical Patients

NCT03926949

Malnutrition Surgery

RECRUITING NA

ERAS Versus ERAS Plus Artificial Nutrition in Open Pancreatoduodenectomy

NCT04438447

Pancreas Disease

UNKNOWN NA

Study Comparing Early and Late Nutrition in Cancer Patients Undergoing Abdominal Surgery

NCT01839617

Cancer Abdominal Surgery Parenteral Nutrition

UNKNOWN NA

Investigating Nutrition and Functional Outcome in Critically Ill Patients

NCT04180852

Neurosurgical Patients Elderly Patients Obese Patients +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In most Latin-American countries individually customized nutrition formulations (CNF) remains the gold-standard for parenteral nutrition in opposition to industrialized ready-to-use parenteral nutrition (RTU). Although CNF is possibly associated with elevated infection rates, delay in the start of enteral nutrition and worse clinical outcomes there is no strong scientific evidence in the literature to support that the use of RTU is indeed associated with better clinical outcomes.

The use of closed ready-to-use parenteral nutrition systems is probably associated with less infection rates and better clinical outcomes including less time at the hospital and at the intensive care unit, less consumption of hospital resources and most likely lower mortality rates as well as early initiation of parenteral nutrition support. The aim of this study is to evaluate all the above mentioned parameters in contrast with those observed when using CNF parenteral nutrition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parenteral Nutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients will receive RTU TPN with olive-oil as the primary source of lipids

Group Type EXPERIMENTAL

RTU TPN with olive oil as the primary lipid source

Intervention Type DIETARY_SUPPLEMENT

RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.

2

CNF parenteral nutrition made with olive oil as the primary source of lipids

Group Type ACTIVE_COMPARATOR

CNF Parenteral nutrition

Intervention Type OTHER

CNF parenteral nutrition made with olive oil as the primary source of lipids

3

CNF parenteral nutrition made with LCT/MCT as the primary source of lipids

Group Type ACTIVE_COMPARATOR

CNF parenteral nutrition

Intervention Type OTHER

3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RTU TPN with olive oil as the primary lipid source

RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.

Intervention Type DIETARY_SUPPLEMENT

CNF Parenteral nutrition

CNF parenteral nutrition made with olive oil as the primary source of lipids

Intervention Type OTHER

CNF parenteral nutrition

3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OliClinomel, Baxter Healthcare ClinOleic, Baxter Healthcare LCT/MCT providers may vary

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years of age with recommendation to use total parenteral nutrition.
* Caloric goals will be calculated using BEE adjusted by the pathology of the patient. In addition, patients MUST achieve at least once 75% of BEE (calculated using the Harris-Benedict equation) to be considered evaluable. Caloric intake will be accessed in a daily basis.
* This study will be performed in accordance with all ethics statements of the Helsinki's Declaration (52nd General Assembly of the World Medical Association, Edinburgh, Scotland, October, 2000), and of the Nuremberg Code.
* In addition, this study must be approved by the Institutional Review Board before patient enrollment and by the Federal Council of Research and Ethics of the Ministry of Health.
* All participating institutions will also be requested to observe Good Clinical Practice Guidelines and all federal laws and regulations.
* An informed consent will be obtained from all patients or their legal representatives before any study related procedure.

Exclusion Criteria

* Pregnancy or breastfeeding
* Patients under 18 years of age
* Significant limitation of survival prognosis (patients expecting a life survival under 28 days due to a chronic and/or incurable disease such as uncontrolled cancer or other terminal disease)
* Pre-existing chronic renal insufficiency and need of hemodialysis or peritoneal dialysis, participation in other clinical trial less than 3 months before inclusion in this trial
* Head trauma with a Glasgow Come Score (GCS) less or equal to 5
* Severe immunologic suppression (defined as a leukocyte count bellow 5.000 cells/mm3)
* Infection by the human immunodeficiency virus
* Patients with no indication for parenteral feeding or in the imminence of receiving enteral nutrition
* Patients receiving partial parenteral nutrition in order to achieve caloric goal, or patient's, patient's legal representative or physicians decision to exclude patients from this protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No